• Xue Tian, He Zhu, Shibin Du, Xue-Qing Zhang, Fuqing Lin, Fengtao Ji, Yung-Hao Tsou, Zhongyu Li, Yi Feng, Kathryn Ticehurst, Stephen Hannaford, Xiaoyang Xu, and Yuan-Xiang Tao.
• Department of Anesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey; Department of Anesthesiology, Peking University People's Hospital, Beijing, China.
• J Pain. 2021 Feb 1; 22 (2): 180-195.

AbstractThe management of persistent postsurgical pain and neuropathic pain remains a challenge in the clinic. Local anesthetics have been widely used as simple and effective treatment for these 2 disorders, but the duration of their analgesic effect is short. We here reported a new poly lactic-co-glycolic acid (PLGA)-coated ropivacaine that was continuously released in vitro for at least 6 days. Perisciatic nerve injection of the PLGA-coated ropivacaine attenuated paw incision-induced mechanical allodynia and heat hyperalgesia during the incisional pain period, and spared nerve injury-induced mechanical and cold allodynia for at least 7 days postinjection. This effect was dose-dependent. Perisciatic nerve injection of the PLGA-coated ropivacaine did not produce detectable inflammation, tissue irritation, or damage in the sciatic nerve and surrounding muscles at the injected site, dorsal root ganglion, spinal cord, or brain cortex, although the scores for grasping reflex were mildly and transiently reduced in the higher dosage-treated groups. PERSPECTIVE: Given that PLGA is an FDA-approved medical material, and that ropivacaine is used currently in clinical practice, the injectable PLGA-coated ropivacaine represents a new and highly promising avenue in the management of postsurgical pain and neuropathic pain.Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

30 keywords...

hide…